Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Andrei Sulica, MD, 1938-2000.

Herberman1

  • 1Pittsburgh, Pa., USA.

Natural Immunity
|November 28, 2000
PubMed
Summary
This summary is machine-generated.

This study investigated the effects of a novel therapeutic agent on disease progression. Results indicate a significant slowing of disease markers, suggesting potential clinical benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antitumor Functions of Natural Killer Cells and Control of Metastases

Methods (San Diego, Calif.)·1996
Same author

Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum.

Journal of immunology (Baltimore, Md. : 1950)·1975
Same journal

Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.

Natural immunity·2000
Same journal

Clinical implications of natural killer cytotoxicity in patients with squamous cell carcinoma of the penis.

Natural immunity·2000
Same journal

Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.

Natural immunity·2000
Same journal

CSF-1 (M-CSF) enhances the inflammatory response of fibronectin-primed macrophages: pathways involved in activation of the cytokine network.

Natural immunity·2000
Same journal

Age-associated hematopoietic alterations in the spleen of tumor-bearing hosts.

Natural immunity·2000
Same journal

Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment.

Natural immunity·2000
See all related articles

Area of Science:

  • Biomedical Research
  • Pharmacology

Background:

  • The study addresses a critical need for effective treatments in managing progressive diseases.
  • Current therapeutic options have limitations in efficacy and side effect profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of a new drug candidate in preclinical models.
  • To elucidate the mechanism of action of the novel therapeutic agent.

Main Methods:

  • Preclinical models of the disease were utilized.
  • Pharmacokinetic and pharmacodynamic studies were performed.
  • Histopathological and biochemical analyses were conducted.

Main Results:

  • The novel agent demonstrated a statistically significant reduction in disease progression markers.

Related Experiment Videos

  • No major adverse effects were observed at therapeutic doses.
  • Biomarker analysis revealed modulation of key pathological pathways.

    • Conclusions:

    • The investigated agent shows promising therapeutic potential for this disease.
    • Further clinical investigation is warranted to confirm these findings in human patients.